ArticleGenomics & informatics2025
In silico design and evaluation of a multiepitope vaccine against Bordetella pertussis: structural, immunological, and biological properties.
Article in Genomics & informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesDespite widespread vaccination, the increasing incidence of pertussis underscores the urgent need for innovative vaccine strategies. This study aims to design and analyze, using in silico methods, a multiepitope protein that incorporates epitopes from the S1 subunit of pertussis toxin and the type 1 immunodominant domain of filamentous hemagglutinin (F1). The goal is to enhance both systemic and mucosal immunity through the incorporation of the C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE).
methodsUsing reverse vaccinology, we predicted immunogenic epitopes for lymphocytes derived from the S1 and F1 proteins. The epitopes were assembled into a multiepitope construct named mF1S1-C-CPE, which was then evaluated for its physicochemical, immunological, and biological properties. Immunoinformatics tools were employed to analyze antigenicity, allergenicity, and population coverage. Additionally, molecular docking simulations of peptide‒MHC and mF1S1-C-CPE_TLR2/TLR4 binding were conducted.
resultsStructural analysis indicated that the final multiepitope construct maintained stability and solubility in aqueous environments. Immunoinformatic analysis revealed strong immunogenic properties, effectively eliciting both systemic and mucosal immune responses. Molecular docking demonstrated high-affinity binding patterns between the peptides (both individual or within the mF1S1-C-CPE) and corresponding HLA molecules. Additionally, molecular docking simulations of mF1S1-C-CPE and TLR2/TLR4 indicated strong binding affinity to receptors of innate immunity. The construct was predicted to be stable, soluble, and suitable for expression in Escherichia coli (CAI 0.93; GC content 54.9%).
conclusionThis innovative approach holds promise for enhancing pertussis vaccination strategies by improving mucosal immune responses. Further in vivo studies are essential to validate the efficacy of this multiepitope vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.